Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand
type: Article
item type: journalArticle
is part of: AIDS Res Hum Retroviruses
authors: Person
  surname: Briand
  given name: Nelly
authors: Person
  surname: Le Cœur
  given name: Sophie
authors: Person
  surname: Jourdain
  given name: Gonzague
authors: Person
  surname: Hotrawarikarn
  given name: Somboon
authors: Person
  surname: Sirinontakan
  given name: Surat
authors: Person
  surname: Hinjiranandana
  given name: Temsiri
authors: Person
  surname: Kanjanavanit
  given name: Suparat
authors: Person
  surname: Traisathit
  given name: Patrinee
authors: Person
  surname: McIntosh
  given name: Kenneth
authors: Person
  surname: Lallemant
  given name: Marc
subject: Anemia/chemically induced
subject: Confidence Intervals Drug Monitoring Female HIV Infections
subject: Pregnancy Complications, Infectious
subject: Thailand
subject: Zidovudine/ therapeutic use
subject: drug therapy Randomized Controlled Trials as Topic
subject: drug therapy/prevention & control/transmission HIV-1
subject: pathogenicity Hematologic Tests Humans Infant Infant, Newborn Infectious Disease Transmission, Vertical
subject: prevention & control Linear Models Neutropenia/chemically iinduced Neutrophils/virology Pregnancy
abstract: The evolution of hematological parameters in HIV-1-exposed uninfected infants according to various durations of perinatal zidovudine exposure was studied. We used data prospectively collected among 1122 HIV-uninfected formula-fed infants born to HIV-infected mothers who participated in a clinical trial to prevent perinatal transmission in Thailand (PHPT-1). Infants were exposed to different durations of zidovudine both in utero and after birth. Hemoglobin level and leukocyte, absolute neutrophil, and lymphocyte counts were measured at birth and at 6 weeks of age. The association between hematological parameters at birth and the duration of zidovudine exposure in utero was studied using a linear regression model, and changes between birth and 6 weeks of age and the duration of postnatal zidovudine exposure using mixed effects models. At birth, the hemoglobin level was lower in newborns exposed to zidovudine for more than 7.5 weeks in utero (adjusted regression coefficient: -0.6 g/dl; 95% confidence interval: -1.1 to -0.1). Six weeks after birth, the hemoglobin level had decreased faster in infants administered zidovudine for more than 4 weeks (adjusted regression coefficient: -0.1 g/dl; 95% confidence interval: -0.2 to -0.1). The duration of perinatal zidovudine exposure was not associated with the evolution of leukocyte, neutrophil, and lymphocyte counts. Despite the differences in hemoglobin levels, grade 3 or 4 anemia did not significantly differ by maternal or infant zidovudine duration. The clinical impact appeared modest, but longer exposure may warrant close monitoring.
date: 2010
pages: 1163-6
citation key: briandHematologicalSafetyPerinatal2010
short title: Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand
description: 10

AIDS Res Hum Retroviruses
type: Journal
volume: 26
identifier: DOI 10.1089/aid.2010.0034
identifier: ISSN 1931-8405 (Electronic) 0889-2229 (Linking)